PCP
GILD icon

Perbak Capital Partners’s Gilead Sciences GILD Stock Holding History

Perbak Capital Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,968
Closed -$832K – 109
2026
Q1 		$832K Buy
+5,968
New +$836K 0.2% 104
2025
Q2 		– Sell
-2,125
Closed -$238K – 299
2025
Q1 		$238K Buy
+2,125
New +$219K 0.18% 160

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perbak Capital Partners's GILD Position: Q2 2026 in Review

Perbak Capital Partners sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 5,968 shares — an estimated $832K sold.

Perbak Capital Partners first reported a position in GILD in Q1 2025 and held it in 2 quarters. The position peaked at $832K in Q1 2026. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Perbak Capital Partners reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
  • Perbak Capital Partners sold 5,968 Gilead Sciences shares in Q2 2026, an estimated $832K.
  • Perbak Capital Partners first reported a position in Gilead Sciences in Q1 2025 and held it in 2 quarters.
  • Perbak Capital Partners's Gilead Sciences position peaked at $832K in Q1 2026.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Perbak Capital Partners's 13F filing for Q2 2026.